Windtree Announces First Patient Dosed in Phase II Study of Istaroxime in Heart Failure Patients

October 7, 2020

Windtree Announces First Patient Dosed in Phase II Study of Istaroxime in Heart Failure Patients

Windtree Therapeutics, Inc. announced that it has dosed the first patient in its phase II study of istaroxime in patients experiencing early cardiogenic shock. Early cardiogenic shock is one of two developmental programs for istaroxime, with the other program targeting acute heart failure, which is supported by positive phase IIOa and IIb trial results and a FDA Fast Track designation. Fast Track programs put an extra strain on clinical trials logistics, but Yourway is prepared for such challenges.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

SCOPE Supply Chain & Logistics Leadership Summit

February 2-5, 2026
Orlando, Florida

Schedule a Meeting

Global Clinical Supplies Group Asia Pacific Conference

March 10-12, 2026
Conrad Seoul Hotel, South Korea

Schedule a Meeting

Media

Articles

When is it time to switch to a biopharma-specialized courier?

Open chat

Hello! How can I help you?